Vue transversale globale

Toutes les maladies

Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.

Périmètre

Filtrer toute la vue

Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.

Tout réinitialiser Actualisation…
Essais et traitements4050Données cliniques et programmes
Recherches et trouvailles21Pipeline scientifique
Publications4595Références reliées aux maladies
Pistes exploratoires0Hypothèses non validées
8666 résultats correspondants · 41 visibles sur cette page dans le périmètre Toutes les maladies
Niveau clinique

Études et traitements 4050

Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.

Molécule / élément Maladie / population Objectif Phase / stade Statut / preuve Mécanisme / résumé Source Détail
anti-CD19-CAR-T cells NCT06420154 · The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refra… Sclérose en plaques Immunomodulation · Thérapie cellulaire Phase 1 NOT_YET_RECRUITING This is an investigator-initiated trial to evaluate the safety and efficac… À vérifier ClinicalTrials.gov 2026-09-20 04:37:27 Détail
ASP2802 NCT06248086 · A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell L… Sclérose en plaques Immunomodulation · Thérapie cellulaire Phase 1 TERMINATED CAR-T cell therapy is a type of treatment for people with certain lymphoma… À vérifier ClinicalTrials.gov 2026-09-20 04:37:27 Détail
Bexxar NCT00434629 · Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Ce… Sclérose en plaques À vérifier Phase 1 COMPLETED Patients with B-cell lymphoma who relapse after autologous transplant tend… À vérifier ClinicalTrials.gov 2026-09-20 04:37:27 Détail
CD19/CD22 CAR-T NCT04499573 · Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B… Sclérose en plaques Thérapie cellulaire Phase 1/2 ACTIVE_NOT_RECRUITING The purpose of this study is to evaluate the safety and efficiency of auto… À vérifier ClinicalTrials.gov 2026-09-20 04:37:27 Détail
cemacabtagene ansegedleucel NCT06500273 · ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients Wi… Sclérose en plaques À vérifier Phase 2 RECRUITING This is a randomized, open-label study in adult patients who have complete… À vérifier ClinicalTrials.gov 2026-09-20 04:37:27 Détail
CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Deplet… NCT03810196 · CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post… Sclérose en plaques Immunomodulation · Thérapie cellulaire Non applicable RECRUITING The major morbidities of allogeneic hematopoietic stem cell transplant wit… À vérifier ClinicalTrials.gov 2026-09-20 04:37:27 Détail
KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy NCT06590545 · IDEAL — Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis Sclérose en plaques Thérapie cellulaire Phase 1/2 NOT_YET_RECRUITING The goal of this phase I/II clinical trial is to investigate anti-CD 19 ch… À vérifier ClinicalTrials.gov 2026-09-20 04:37:27 Détail
rapcabtagene autoleucel (YTB323) NCT07443137 · CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) Sclérose en plaques Immunomodulation · Thérapie cellulaire Phase 1 NOT_YET_RECRUITING This is an open-label, multi-center, non-confirmatory study to assess the… À vérifier ClinicalTrials.gov 2026-09-20 04:37:27 Détail
rondecabtagene autoleucel NCT07188558 · PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19… Sclérose en plaques Immunomodulation · Thérapie cellulaire Phase 3 RECRUITING This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-… À vérifier ClinicalTrials.gov 2026-09-20 04:37:27 Détail
TC011 single-arm NCT07360288 · TC011_FL_201 — Efficacy and Safety of TC011 in Relapsed or Refractory Follicular… Sclérose en plaques Thérapie cellulaire Phase 2 NOT_YET_RECRUITING This Phase II, multi-center, single-arm, open-label study evaluates the ef… À vérifier ClinicalTrials.gov 2026-09-20 04:37:27 Détail
ThisCART19A with Dose Level 1 NCT05691153 · ThisCART19A for B-NHL Relapsed After Auto-CAR T Sclérose en plaques Thérapie cellulaire Phase 1 UNKNOWN This is a phase 1, single-center, dose selection study to evaluate the eff… À vérifier ClinicalTrials.gov 2026-09-20 04:37:27 Détail
Rituximab NCT03636503 · Rituximab + Immunotherapy in Follicular Lymphoma Sclérose en plaques À vérifier Phase 1 TERMINATED The primary objective of this phase III trial is to investigate if Rituxim… À vérifier ClinicalTrials.gov 2026-09-20 04:37:26 Détail
Rituximab NCT00006669 · Rituximab Followed by Combination Chemotherapy in Treating Patients With Refract… Sclérose en plaques À vérifier Phase 2 WITHDRAWN The primary objective of this phase III trial is to investigate if Rituxim… À vérifier ClinicalTrials.gov 2026-09-20 04:37:26 Détail
SCT400 plus CHOP NCT02772822 · A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxyd… Sclérose en plaques Immunomodulation Phase 3 UNKNOWN The primary objective of the study is to assess the efficiency of SCT400 p… À vérifier ClinicalTrials.gov 2026-09-20 04:37:26 Détail
Armored and GPC3-targeted autologous CAR T-cell NCT06590246 · A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocell… Sclérose en plaques À vérifier Phase 1/2 RECRUITING This single-arm, open-label multicenter Phase I/II study will evaluate the… À vérifier ClinicalTrials.gov 2026-09-20 04:37:25 Détail
C-CAR031 NCT05155189 · A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031… Sclérose en plaques Immunomodulation · Thérapie cellulaire Phase 1 RECRUITING A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier ClinicalTrials.gov 2026-09-20 04:37:25 Détail
C-CAR031 NCT07444281 · An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Ad… Sclérose en plaques À vérifier Phase 1 RECRUITING A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier ClinicalTrials.gov 2026-09-20 04:37:25 Détail
CD19/CD20-directed Chimeric Antigen Receptor T Cells NCT05149391 · A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgk… Sclérose en plaques Immunomodulation Phase 1 COMPLETED This is a single-center, open-label study to evaluate the safety and effic… À vérifier ClinicalTrials.gov 2026-09-20 04:37:25 Détail
Prizloncabtagene Autoleucel NCT04317885 · A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects Sclérose en plaques À vérifier Phase 1 COMPLETED The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier ClinicalTrials.gov 2026-09-20 04:37:25 Détail
Prizloncabtagene Autoleucel NCT04693676 · A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Ly… Sclérose en plaques À vérifier Phase 1 UNKNOWN The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier ClinicalTrials.gov 2026-09-20 04:37:25 Détail
Découverte scientifique

Recherches et trouvailles 21

Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.

Molécule / élément Maladie / population Objectif Phase / stade Statut / preuve Mécanisme / résumé Source Détail
4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation Sclérose latérale amyotrophique Neuroprotection · Immunomodulation Découverte fondamentale Exploratoire Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… Revue scientifique 2024-07-01 Détail
Bibliographie

Publications 4595

Références bibliographiques de la base locale et accès à leur source originale.

Molécule / élément Maladie / population Objectif Phase / stade Statut / preuve Mécanisme / résumé Source Détail
Chronic 3.5 GHz radiofrequency exposure is associated with behavioral… Sham · PMID 42566258 Migraine · Sclérose en plaques À vérifier Publication PubMed Voir la publication source Chronic exposure to mid-band radiofrequency (RF) electromagnetic fields at 3.5 GHz is increasingly relevant to modern w… International journal of radiation biology 2026-08-08 00:55:59 Source
Efficacy and safety of acupuncture treatment for depression: A system… Sham · PMID 42566610 Migraine · Sclérose en plaques À vérifier Publication PubMed Voir la publication source A common mental health issue with major worldwide repercussions is depression. Psychological therapy and pharmaceutical… Medicine 2026-08-08 00:55:59 Source
Mind the dog: real dogs elicit emotional and mental state language in… EMST · PMID 42531737 Sclérose en plaques À vérifier Publication PubMed Voir la publication source Growing up with a pet, especially a dog, can play a significant and emotionally meaningful role in a child's life. Livi… Journal of experimental child psychology 2026-08-08 00:55:58 Source
Physiologic Adaptations to Modifying Resistive Load and Time Under Te… EMST · PMID 42531563 Sclérose en plaques À vérifier Publication PubMed Voir la publication source The purpose of this study was to test the impact of modifying resistive load and time under tension (TUT) on respirator… Journal of speech, language, and hearing research : JS… 2026-08-08 00:55:58 Source
Effects of respiratory muscle training on respiratory function, exerc… Inspiratory Muscle Training in Individuals With Multiple Sclerosis · PMID 41678965 Sclérose en plaques À vérifier Publication PubMed Voir la publication source This systematic review and meta-analysis aimed to evaluate the effects of respiratory muscle training (RMT) on respirat… Multiple sclerosis and related disorders 2026-08-08 00:55:57 Source
Effects of respiratory muscle training on respiratory function, trunk… Inspiratory Muscle Training in Individuals With Multiple Sclerosis · PMID 41981242 Sclérose en plaques Traitement symptomatique Publication PubMed Voir la publication source Multiple sclerosis (MS) is a chronic condition affecting the central nervous system, often causing fatigue, postural in… Scientific reports 2026-08-08 00:55:57 Source
Drug-induced dysphagia: Analysis of age and time of onset profiles us… paroxetine · PMID 42544525 Migraine · Sclérose en plaques · Sclérose en plaques À vérifier Publication PubMed Voir la publication source To investigate differences in drug-induced dysphagia profiles among causative drugs, with a focus on reporting risk, pa… International journal of clinical pharmacology and the… 2026-08-08 00:55:56 Source
Effects of antidepressant administration on physical performance and… paroxetine · PMID 42560424 Migraine · Sclérose en plaques · Sclérose en plaques À vérifier Publication PubMed Voir la publication source Antidepressants are commonly prescribed in athletes with depressive disorders, yet their potential effects on physical… International journal of clinical pharmacy 2026-08-08 00:55:56 Source
Can Omegaven Avoid the Destructive Effect of Procarbazine Over Ovaria… blood sample to analyse AMH level on the serum · PMID 42440830 Sclérose en plaques Immunomodulation Publication PubMed Voir la publication source Procarbazine, an alkylating agent, depletes ovarian reserve. Omegaven exhibits anti-apoptotic, anti-inflammatory, and a… Reproductive medicine and biology 2026-08-08 00:55:55 Source
GPR17 - orphan G protein-coupled receptor with therapeutic potential. PTD802 · PMID 40544085 Sclérose en plaques Remyélinisation Publication PubMed Voir la publication source The orphan G protein-coupled receptor (GPCR) GPR17, whose physiological agonist remains unknown, has emerged as a promi… Trends in pharmacological sciences 2026-08-08 00:55:55 Source
Serum anti-Müllerian hormone response to pyrroloquinoline quinone sup… blood sample to analyse AMH level on the serum · PMID 42500134 Sclérose en plaques Remyélinisation indirecte / réparation · Neuroprotection Publication PubMed Voir la publication source Oocyte maturation requires substantial ATP, and the resulting oxidative stress may impair follicular development. Pyrro… Frontiers in endocrinology 2026-08-08 00:55:55 Source
Experience of using anti-CD 20 therapies in multiple sclerosis patien… Ocrelizumab 600 mg · PMID 41669530 Sclérose en plaques Traitement symptomatique Publication PubMed Voir la publication source The objective of the study was to evaluate the safety and efficacy of ocrelizumab (OCR) and rituximab (RTX) in multiple… Frontiers in neurology 2026-08-08 00:55:53 Source
Differential safety profiles of disease-modifying therapies in MS: Ag… Ocrelizumab 300 mg · PMID 42107470 Sclérose en plaques Ralentissement de la progression Publication PubMed Voir la publication source Age and sex may modulate adverse events (AE) under disease-modifying therapies (DMTs) in Multiple Sclerosis (MS), yet c… Multiple sclerosis and related disorders 2026-08-08 00:55:52 Source
Reinitiating ocrelizumab with a full 600 mg dose after extended treat… Ocrelizumab 300 mg · PMID 42153199 Sclérose en plaques À vérifier Publication PubMed Voir la publication source Infusion-related reactions (IRRs) are a common side-effect of ocrelizumab (OCR), with the highest risk occurring during… Multiple sclerosis journal - experimental, translation… 2026-08-08 00:55:52 Source
6-Mercaptopurine metabolic profiles and clinical outcomes in TPMT and… Intervention group IM-IM · PMID 42249522 Sclérose en plaques À vérifier Publication PubMed Voir la publication source This study aimed to investigate the real-world profiles of 6-mercaptopurine (6-MP) treatment in various TPMT/NUDT15 phe… British journal of clinical pharmacology 2026-08-08 00:55:51 Source
Diagnostic value of combined flow cytometry-based detection of periph… Intervention group IM-IM · PMID 42403386 Sclérose en plaques Immunomodulation Publication PubMed Voir la publication source Pediatric infectious mononucleosis (IM) caused by Epstein-Barr virus (EBV) poses diagnostic challenges due to overlappi… Frontiers in pediatrics 2026-08-08 00:55:51 Source
Can a virtual reality tool detect minor executive functions impairmen… Comparison of Two Different Virtual Reality Methods in Patients With Multiple Sclerosis · PMID… Sclérose en plaques À vérifier Publication PubMed Voir la publication source Traditional neuropsychological tests do not always identify executive disorders in patients with multiple sclerosis (MS… Revue neurologique 2026-08-08 00:55:50 Source
Evidence of attentional impairments using virtual driving simulation… Comparison of Two Different Virtual Reality Methods in Patients With Multiple Sclerosis · PMID… Sclérose en plaques Ralentissement de la progression Publication PubMed Voir la publication source Detection of attentional disorders in complex situation related to daily life activities in multiple sclerosis patients… Multiple sclerosis and related disorders 2026-08-08 00:55:50 Source
Salvage treatment of forearm arteriovenous fistula with small caliber… Venous PTA · PMID 38087648 Sclérose en plaques À vérifier Publication PubMed Voir la publication source Dysfunctional distal arteriovenous fistulas (AVFs) with small caliber distal inflow arteries theoretically require perc… The journal of vascular access 2026-08-08 00:55:48 Source
Surgical management of post-thrombotic syndrome in chronic venous tho… Venous PTA · PMID 33429091 Sclérose en plaques Ralentissement de la progression · Traitement symptomatique · Thérapie génique Publication PubMed Voir la publication source Venous thoracic outlet syndrome (VTOS) is considered chronic when symptoms and venous stenosis or occlusion are present… Journal of vascular surgery. Venous and lymphatic diso… 2026-08-08 00:55:48 Source
Exploration — prudence

Pistes exploratoires 0

Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.

Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
Molécule / élément Maladie / population Objectif Phase / stade Statut / preuve Mécanisme / résumé Source Détail
Aucune piste exploratoire ne correspond aux filtres.